Patents by Inventor Curtis Harwig

Curtis Harwig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemokine receptor binding heterocyclic compounds with enhanced efficacy
    Patent number: 7354932
    Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: April 8, 2008
    Assignee: Anormed, Inc.
    Inventors: Gary Bridger, Al Kaller, Curtis Harwig, Renato Skerlj, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
  • Chemokine receptor binding heterocyclic compounds
    Patent number: 7312234
    Abstract: Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: December 25, 2007
    Assignee: AnorMED
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
  • CXCR4 chemokine receptor binding compounds
    Patent number: 7291631
    Abstract: The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: November 6, 2007
    Assignee: Genzyme Corporation
    Inventors: Gary J. Bridger, Ernest J. McEachern, Renato Skerlj, Dominique Schols, Ian Baird, Al Kaller, Curtis Harwig, Yongbao Zhu, Gang Chen, Krystyna Skupinska
  • Chemokine receptor binding compounds
    Publication number: 20070066624
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Application
    Filed: August 16, 2006
    Publication date: March 22, 2007
    Applicant: AnorMED, Inc.
    Inventors: Yuanxi Zhou, Elyse Bourque, Yongbao Zhu, Ernest McEachern, Curtis Harwig, Renato Skerlj, Gary Bridger, Tong-Shuang Li, Markus Metz
  • Chemokine receptor binding heterocyclic compounds
    Patent number: 7183273
    Abstract: Heterocyclic compounds that bind chemokine receptors and inhibit the binding of their natural ligands are disclosed. The invention compounds are protective against infection by HIV and exert effects characteristic of antagonists to the CXCR4 receptor.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: February 27, 2007
    Assignee: AnorMED, Inc.
    Inventors: Gary J. Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols
  • Chemokine receptor binding heterocyclic compounds
    Publication number: 20060264434
    Abstract: This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines.
    Type: Application
    Filed: July 27, 2006
    Publication date: November 23, 2006
    Applicant: AnorMED Inc.
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor Wilson, Jason Crawford, Ernest McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols
  • Chemokine receptor binding heterocyclic compounds
    Publication number: 20060252795
    Abstract: Compounds which modulate chemokine receptor activities are disclosed. These compounds are preferably tertiary amines comprising tetrahydroquinoline and benzimidazole.
    Type: Application
    Filed: July 14, 2006
    Publication date: November 9, 2006
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor Wilson, Jason Crawford, Ernest McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Smith, Maria Di Fluri
  • Chemokine receptor binding heterocyclic compounds
    Patent number: 7091217
    Abstract: Compounds which modulate chemokine receptor activities are disclosed. These compounds are preferably tertiary amines comprising tetrahydroquinoline and benzimidazole.
    Type: Grant
    Filed: March 11, 2004
    Date of Patent: August 15, 2006
    Assignee: AnorMED, Inc.
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
  • Chemokine receptor binding heterocyclic compounds
    Patent number: 7084155
    Abstract: Novel compounds that are useful for targeting chemokine receptors are disclosed. These compounds are complex tertiary amines.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: August 1, 2006
    Assignee: AnorMED
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
  • Chemokine receptor binding heterocyclic compounds
    Publication number: 20060128750
    Abstract: Tertiary amine compounds that bind chemokine receptors such as CXCR4 and CCR5 are disclosed.
    Type: Application
    Filed: February 2, 2006
    Publication date: June 15, 2006
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor Wilson, Jason Crawford, Ernest McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Smith, Maria Di Fluri
  • Chemokine receptor binding heterocyclic compounds with enhanced efficacy
    Publication number: 20060100240
    Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Application
    Filed: December 13, 2005
    Publication date: May 11, 2006
    Inventors: Gary Bridger, Ai Kaller, Curtis Harwig, Renato Skerlj, David Bogucki, Trevor Wilson, Jason Crawford, Ernest McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Smith, Maria Di Fluri
  • Chemokine receptor binding heterocyclic compounds with enhanced efficacy
    Publication number: 20050059702
    Abstract: Compounds that interact with the CXCR4 receptor are described. These compounds are useful in treating, for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in methods to elevate progenitor and stem cell counts as well as methods to elevate white blood cell counts.
    Type: Application
    Filed: April 22, 2004
    Publication date: March 17, 2005
    Inventors: Gary Bridger, Ernest Mceachern, Renato Skerlj, Dominique Schols, Ian Baird, Ai Kaller, Curtis Harwig, Yongbao Zhu, Gang Chen, Krystyna Skupinska, Markus Metz
  • Chemokine receptor binding heterocyclic compounds
    Patent number: 6864265
    Abstract: Compounds that bind to chemokine receptors such as CXCR4 and CCR5 demonstrate protective effects against infection of cells by human immunodeficiency virus are disclosed. These compounds contain a tertiary amine[[s]] linked to a core nitrogen via an aromatic or heteroaromatic moiety.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: March 8, 2005
    Assignee: AnorMED, Inc.
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. Mceachern, Bern Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis, Rosaria Maria Di Fluri
  • Chemokine receptor binding heterocyclic compounds
    Publication number: 20050026942
    Abstract: Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators.
    Type: Application
    Filed: August 9, 2004
    Publication date: February 3, 2005
    Applicant: AnorMED
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor Wilson, Jason Crawford, Ernest McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Smith, Maria Di Fluri
  • Chemokine receptor binding heterocyclic compounds
    Patent number: 6835731
    Abstract: Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: December 28, 2004
    Assignee: AnorMED, Inc.
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis, Rosaria Maria Di Fluri
  • Chemokine receptor binding heterocyclic compounds
    Publication number: 20040235823
    Abstract: This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines.
    Type: Application
    Filed: April 30, 2004
    Publication date: November 25, 2004
    Inventors: Gary J. Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols
  • Chemokine receptor binding heterocyclic compounds
    Publication number: 20040220207
    Abstract: Novel compounds that are useful for targeting chemokine receptors are disclosed. These compounds are complex tertiary amines.
    Type: Application
    Filed: June 1, 2004
    Publication date: November 4, 2004
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
  • Chemokine receptor binding heterocyclic compounds
    Publication number: 20040171638
    Abstract: Compounds which modulate chemokine receptor activities are disclosed. These compounds are preferably tertiary amines comprising tetrahydroquinoline and benzimidazole.
    Type: Application
    Filed: March 11, 2004
    Publication date: September 2, 2004
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
  • Chemokine receptor binding heterocyclic compounds
    Patent number: 6750348
    Abstract: This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines.
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: June 15, 2004
    Assignee: AnorMED, Inc.
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols
  • Chemokine receptor binding heterocyclic compounds
    Patent number: 6734191
    Abstract: Compounds which modulate chemokine receptor activities are disclosed. These compounds are preferably tertiary amines comprising tetrahydroquinoline and benzimidazole.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: May 11, 2004
    Assignee: AnorMED, Inc.
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bern Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis, Rosaria Maria Di Fluri